A real world-perspective of CD123 expression in acute leukemia as promising biomarker to predict treatment outcome in B-ALL and AML
CD123 is overexpressed in many hematological malignancies and found to be useful in characterising leukemic blasts of both acute myeloid leukemia (AML) and B-acute lymphoblastic leukemia (B-ALL). CD123 has been recently found to be a marker of leukemic stem cells and its utility to measure residual disease and potential role in disease relapse is under evaluation. Herein, we have evaluated the expression of CD123 in 757 samples of acute leukaemia including 479 treatment na ïve and 278 follow-up samples and compared with post-induction morphological remission (CR) and measurable residual disease (MRD) status.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Nupur Das, Ritu Gupta, Sanjeev Kumar Gupta, Sameer Bakhshi, Ankit Malhotra, Sandeep Rai, Saroj Singh, Vijay Kumar Prajapati, Ranjeet Kumar Sahoo, Ajay Gogia, Atul Sharma, Lalit Kumar Tags: Original Study Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Hematology | Leukemia | Lymphoma | Myeloma | Stem Cell Therapy | Stem Cells | Study